My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Result Updates | Nov 11th 2016

ICICI Bank Ltd

CMP : 277Target Price : 315

ICICI Banks 2QFY17 results have been encouraging. While slippages remained high, large part of that came from the watch list. The bank has utilized part of the proceeds from stake sale in insurance business towards provisions. Management commentary also remained optimistic, as no addition is expected to the watch list; sharp deterioration..

View As PDF

Result Updates | Nov 11th 2016

Cipla Ltd

CMP : 564Target Price : 490

Cipla posted numbers lower than expected for 2QFY2017. The company posted sales of Rs3,672cr vs. Rs3,737cr expected, registering a yoy growth of 8.7%, mainly aided by domestic formulations. Domestic formulation (Rs1,522cr) grew by 11.3% yoy, while exports (Rs2150cr) grew by 7.5% yoy. On the operating front, the EBITDA margin came in at 16..

View As PDF

Sort By

Result Updates | Nov 11th 2016

Lupin Ltd

CMP : 1,493
Target Price : 1,809

Lupin posted results lower than expected. Sales came in at Rs4,212cr vs. Rs4,300cr expected, registering a yoy growth of 31.9%, mainly aided by exports. The sales growth was driven by Formulations sales (Rs3,919.3cr), posting a yoy growth of 37.1%; while API sales (Rs291.9cr) posted a yoy de-growth of 12.3%. On the operating front, the EB..

Result Updates | Nov 10th 2016

Indoco Remedies Ltd

CMP : 277
Target Price : 240

Indoco Remedies posted sales of Rs276cr vs. Rs248cr in 2QFY16, up by 11.6% yoy, mainly on back of domestic sales (Rs168.8cr, which grew by 22.0% yoy). Overall, the formulations, which posted sales of RS261.4cr grew, by 13.0% yoy. The API (Rs135.9cr) dipped by 11.0% yoy. On the operating front, the gross margin came in at 64.9% (65.0% expe..

Result Updates | Nov 10th 2016

Sanofi India Ltd

CMP : 4,277
Target Price :

Sanofi India posted results and are below expectations on all fronts. The sales came in at Rs583cr vs. Rs600cr expected, posting a yoy growth of 5.4%. According to AIOCD, secondary sales, growth for Sanofi India was double digit. According to AIOCD, regulatory actions will have negative one-time impact of ~2% on sales of the company. We e..

Result Updates | Nov 09th 2016

Glaxosmithkline Pharma Ltd

CMP : 2,719
Target Price :

For 2QFY2017, sales stood at Rs783cr vs. Rs700cr expected and vs. Rs700cr in 2QFY2016, a yoy growth of 11.8%. On the operating front, the OPM came in at 15.9% vs. 17.2% in 2QFY2016 and vs. 17.0% expected. The company’s OPM was impacted by other expenses, which grew by 40.5% yoy. Thus, the company posted an Adj. net profit of Rs98cr vs. Rs..

Result Updates | Nov 08th 2016

Amara Raja Batteries Ltd

CMP : 1,010
Target Price : 1,167

We believe that ARBL is likely to continue gaining market share in the automotive battery segment. The strategy followed by automotive OEMs of sourcing from multiple vendors as against having a single vendor is likely to benefit ARBL. Further, with the company’s strengthening distribution network in the Western and Eastern markets, we exp..

Result Updates | Nov 07th 2016

Maruti Suzuki India Ltd

CMP : 5,715
Target Price : 6,006

Maruti Suzuki reported strong Q2FY2017 numbers with expansion in margins. We assume double digit revenue growth in our forecast over strong demand in domestic markets and high production abilities after commissioning of Gujarat plant in Q4FY2017E. Given the new launches, lower petrol prices and its strong brand, MSIL is expected to gain m..

Result Updates | Nov 07th 2016

UPL Ltd

CMP : 672
Target Price :

For 2QFY2017, United Phosphorous (UPL) posted a growth of 7.2% yoy in sales to Rs3,510cr. The volume growth during the period was of 23% yoy, while price decrease contributed around 5% yoy. The exchange rate, on the other hand, had a positive impact of 1% yoy. Including Advanta sales, the company posted sales of `3510cr, posting a yoy gro..

Result Updates | Nov 07th 2016

Dr Reddys Laboratories Ltd

CMP : 3,077
Target Price :

Dr. Reddy’s Laboratories (DRL) posted results lower than expected on net profit front. While the sales were marginally higher than expected, operating profit was much lower than expected. In INR terms, the consolidated revenues came in at Rs3,586cr (vs. Rs3,500cr expected vs. Rs3,989cr in 2QFY2016), down by 10.1% yoy, mainly driven by pre..

Result Updates | Nov 07th 2016

Alembic Pharmaceuticals Ltd

CMP : 676
Target Price :

Alembic Pharmaceuticals posted sales of Rs872cr (vs. Rs1,008cr in 2QFY2016), a dip of 13.5% yoy, mainly on back of base effect. International business declined owing to lower contribution from Abilify. On the operating front, the gross margin is expected to come in at 72.5% (vs. 77.5% in 2QFY2016) and EBIDTA margin at 20.3% (vs. 37.2% in ..

Result Updates | Nov 07th 2016

Cadila Healthcare Ltd

CMP : 390
Target Price :

For 2QFY2017, Cadila Healthcare posted lower than expected results with sales at Rs2,336cr (vs. Rs2,737cr expected vs. Rs2,267cr in 2QFY2016), a yoy growth of 3.1%. On the operating front, the EBITDA margin came in at 21.4% (vs. 21.7% expected vs. 20.3% in 2QFY2016). The dip in the OPM was saved in spite of an underperformance on the sale..